Cargando…

Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan

BACKGROUND: Computed tomography (CT) imaging and artificial intelligence (AI)-based analyses have aided in the diagnosis and prediction of the severity of COVID-19. However, the potential of AI-based CT quantification of pneumonia in assessing patients with COVID-19 has not yet been fully explored....

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Hiromu, Maetani, Tomoki, Chubachi, Shotaro, Tanabe, Naoya, Shiraishi, Yusuke, Asakura, Takanori, Namkoong, Ho, Shimada, Takashi, Azekawa, Shuhei, Otake, Shiro, Nakagawara, Kensuke, Fukushima, Takahiro, Watase, Mayuko, Terai, Hideki, Sasaki, Mamoru, Ueda, Soichiro, Kato, Yukari, Harada, Norihiro, Suzuki, Shoji, Yoshida, Shuichi, Tateno, Hiroki, Yamada, Yoshitake, Jinzaki, Masahiro, Hirai, Toyohiro, Okada, Yukinori, Koike, Ryuji, Ishii, Makoto, Hasegawa, Naoki, Kimura, Akinori, Imoto, Seiya, Miyano, Satoru, Ogawa, Seishi, Kanai, Takanori, Fukunaga, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552312/
https://www.ncbi.nlm.nih.gov/pubmed/37798709
http://dx.doi.org/10.1186/s12931-023-02530-2
_version_ 1785115934961172480
author Tanaka, Hiromu
Maetani, Tomoki
Chubachi, Shotaro
Tanabe, Naoya
Shiraishi, Yusuke
Asakura, Takanori
Namkoong, Ho
Shimada, Takashi
Azekawa, Shuhei
Otake, Shiro
Nakagawara, Kensuke
Fukushima, Takahiro
Watase, Mayuko
Terai, Hideki
Sasaki, Mamoru
Ueda, Soichiro
Kato, Yukari
Harada, Norihiro
Suzuki, Shoji
Yoshida, Shuichi
Tateno, Hiroki
Yamada, Yoshitake
Jinzaki, Masahiro
Hirai, Toyohiro
Okada, Yukinori
Koike, Ryuji
Ishii, Makoto
Hasegawa, Naoki
Kimura, Akinori
Imoto, Seiya
Miyano, Satoru
Ogawa, Seishi
Kanai, Takanori
Fukunaga, Koichi
author_facet Tanaka, Hiromu
Maetani, Tomoki
Chubachi, Shotaro
Tanabe, Naoya
Shiraishi, Yusuke
Asakura, Takanori
Namkoong, Ho
Shimada, Takashi
Azekawa, Shuhei
Otake, Shiro
Nakagawara, Kensuke
Fukushima, Takahiro
Watase, Mayuko
Terai, Hideki
Sasaki, Mamoru
Ueda, Soichiro
Kato, Yukari
Harada, Norihiro
Suzuki, Shoji
Yoshida, Shuichi
Tateno, Hiroki
Yamada, Yoshitake
Jinzaki, Masahiro
Hirai, Toyohiro
Okada, Yukinori
Koike, Ryuji
Ishii, Makoto
Hasegawa, Naoki
Kimura, Akinori
Imoto, Seiya
Miyano, Satoru
Ogawa, Seishi
Kanai, Takanori
Fukunaga, Koichi
author_sort Tanaka, Hiromu
collection PubMed
description BACKGROUND: Computed tomography (CT) imaging and artificial intelligence (AI)-based analyses have aided in the diagnosis and prediction of the severity of COVID-19. However, the potential of AI-based CT quantification of pneumonia in assessing patients with COVID-19 has not yet been fully explored. This study aimed to investigate the potential of AI-based CT quantification of COVID-19 pneumonia to predict the critical outcomes and clinical characteristics of patients with residual lung lesions. METHODS: This retrospective cohort study included 1,200 hospitalized patients with COVID-19 from four hospitals. The incidence of critical outcomes (requiring the support of high-flow oxygen or invasive mechanical ventilation or death) and complications during hospitalization (bacterial infection, renal failure, heart failure, thromboembolism, and liver dysfunction) was compared between the groups of pneumonia with high/low-percentage lung lesions, based on AI-based CT quantification. Additionally, 198 patients underwent CT scans 3 months after admission to analyze prognostic factors for residual lung lesions. RESULTS: The pneumonia group with a high percentage of lung lesions (N = 400) had a higher incidence of critical outcomes and complications during hospitalization than the low percentage group (N = 800). Multivariable analysis demonstrated that AI-based CT quantification of pneumonia was independently associated with critical outcomes (adjusted odds ratio [aOR] 10.5, 95% confidence interval [CI] 5.59–19.7), as well as with oxygen requirement (aOR 6.35, 95% CI 4.60–8.76), IMV requirement (aOR 7.73, 95% CI 2.52–23.7), and mortality rate (aOR 6.46, 95% CI 1.87–22.3). Among patients with follow-up CT scans (N = 198), the multivariable analysis revealed that the pneumonia group with a high percentage of lung lesions on admission (aOR 4.74, 95% CI 2.36–9.52), older age (aOR 2.53, 95% CI 1.16–5.51), female sex (aOR 2.41, 95% CI 1.13–5.11), and medical history of hypertension (aOR 2.22, 95% CI 1.09–4.50) independently predicted persistent residual lung lesions. CONCLUSIONS: AI-based CT quantification of pneumonia provides valuable information beyond qualitative evaluation by physicians, enabling the prediction of critical outcomes and residual lung lesions in patients with COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02530-2.
format Online
Article
Text
id pubmed-10552312
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-105523122023-10-06 Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan Tanaka, Hiromu Maetani, Tomoki Chubachi, Shotaro Tanabe, Naoya Shiraishi, Yusuke Asakura, Takanori Namkoong, Ho Shimada, Takashi Azekawa, Shuhei Otake, Shiro Nakagawara, Kensuke Fukushima, Takahiro Watase, Mayuko Terai, Hideki Sasaki, Mamoru Ueda, Soichiro Kato, Yukari Harada, Norihiro Suzuki, Shoji Yoshida, Shuichi Tateno, Hiroki Yamada, Yoshitake Jinzaki, Masahiro Hirai, Toyohiro Okada, Yukinori Koike, Ryuji Ishii, Makoto Hasegawa, Naoki Kimura, Akinori Imoto, Seiya Miyano, Satoru Ogawa, Seishi Kanai, Takanori Fukunaga, Koichi Respir Res Research BACKGROUND: Computed tomography (CT) imaging and artificial intelligence (AI)-based analyses have aided in the diagnosis and prediction of the severity of COVID-19. However, the potential of AI-based CT quantification of pneumonia in assessing patients with COVID-19 has not yet been fully explored. This study aimed to investigate the potential of AI-based CT quantification of COVID-19 pneumonia to predict the critical outcomes and clinical characteristics of patients with residual lung lesions. METHODS: This retrospective cohort study included 1,200 hospitalized patients with COVID-19 from four hospitals. The incidence of critical outcomes (requiring the support of high-flow oxygen or invasive mechanical ventilation or death) and complications during hospitalization (bacterial infection, renal failure, heart failure, thromboembolism, and liver dysfunction) was compared between the groups of pneumonia with high/low-percentage lung lesions, based on AI-based CT quantification. Additionally, 198 patients underwent CT scans 3 months after admission to analyze prognostic factors for residual lung lesions. RESULTS: The pneumonia group with a high percentage of lung lesions (N = 400) had a higher incidence of critical outcomes and complications during hospitalization than the low percentage group (N = 800). Multivariable analysis demonstrated that AI-based CT quantification of pneumonia was independently associated with critical outcomes (adjusted odds ratio [aOR] 10.5, 95% confidence interval [CI] 5.59–19.7), as well as with oxygen requirement (aOR 6.35, 95% CI 4.60–8.76), IMV requirement (aOR 7.73, 95% CI 2.52–23.7), and mortality rate (aOR 6.46, 95% CI 1.87–22.3). Among patients with follow-up CT scans (N = 198), the multivariable analysis revealed that the pneumonia group with a high percentage of lung lesions on admission (aOR 4.74, 95% CI 2.36–9.52), older age (aOR 2.53, 95% CI 1.16–5.51), female sex (aOR 2.41, 95% CI 1.13–5.11), and medical history of hypertension (aOR 2.22, 95% CI 1.09–4.50) independently predicted persistent residual lung lesions. CONCLUSIONS: AI-based CT quantification of pneumonia provides valuable information beyond qualitative evaluation by physicians, enabling the prediction of critical outcomes and residual lung lesions in patients with COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02530-2. BioMed Central 2023-10-05 2023 /pmc/articles/PMC10552312/ /pubmed/37798709 http://dx.doi.org/10.1186/s12931-023-02530-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tanaka, Hiromu
Maetani, Tomoki
Chubachi, Shotaro
Tanabe, Naoya
Shiraishi, Yusuke
Asakura, Takanori
Namkoong, Ho
Shimada, Takashi
Azekawa, Shuhei
Otake, Shiro
Nakagawara, Kensuke
Fukushima, Takahiro
Watase, Mayuko
Terai, Hideki
Sasaki, Mamoru
Ueda, Soichiro
Kato, Yukari
Harada, Norihiro
Suzuki, Shoji
Yoshida, Shuichi
Tateno, Hiroki
Yamada, Yoshitake
Jinzaki, Masahiro
Hirai, Toyohiro
Okada, Yukinori
Koike, Ryuji
Ishii, Makoto
Hasegawa, Naoki
Kimura, Akinori
Imoto, Seiya
Miyano, Satoru
Ogawa, Seishi
Kanai, Takanori
Fukunaga, Koichi
Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title_full Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title_fullStr Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title_full_unstemmed Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title_short Clinical utilization of artificial intelligence-based COVID-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in Japan
title_sort clinical utilization of artificial intelligence-based covid-19 pneumonia quantification using chest computed tomography – a multicenter retrospective cohort study in japan
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552312/
https://www.ncbi.nlm.nih.gov/pubmed/37798709
http://dx.doi.org/10.1186/s12931-023-02530-2
work_keys_str_mv AT tanakahiromu clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT maetanitomoki clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT chubachishotaro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT tanabenaoya clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT shiraishiyusuke clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT asakuratakanori clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT namkoongho clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT shimadatakashi clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT azekawashuhei clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT otakeshiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT nakagawarakensuke clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT fukushimatakahiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT watasemayuko clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT teraihideki clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT sasakimamoru clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT uedasoichiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT katoyukari clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT haradanorihiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT suzukishoji clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT yoshidashuichi clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT tatenohiroki clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT yamadayoshitake clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT jinzakimasahiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT hiraitoyohiro clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT okadayukinori clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT koikeryuji clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT ishiimakoto clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT hasegawanaoki clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT kimuraakinori clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT imotoseiya clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT miyanosatoru clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT ogawaseishi clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT kanaitakanori clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan
AT fukunagakoichi clinicalutilizationofartificialintelligencebasedcovid19pneumoniaquantificationusingchestcomputedtomographyamulticenterretrospectivecohortstudyinjapan